BioPharma Resources

Drug Trial Radar · NCT06358950

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)

A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

92

Actual

Start

Mar 24, 2024

Primary completion

Jun 19, 2025

Study completion Jul 31, 2025

Sponsor

Lead sponsor
Alkermes, Inc.Industry
Sponsor type
Industry
First posted
Apr 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to assess the safety and efficacy of ALKS 2680 compared to placebo, including whether participants taking ALKS 2680 experience a greater decrease in sleepiness and a decrease in cataplexy ("sudden loss of muscle control"), compared to participants taking placebo alone.

Conditions

  • Narcolepsy Type 1

Interventions

  • ALKS 2680Drug

    Oral tablet of ALKS 2680 for once daily administration

  • PlaceboDrug

    Oral tablet containing matching placebo for once daily administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Mean Sleep Latency (MSL) on the Maintenance of Wakefulness Test (MWT) from baseline to Week 6Time frame: Baseline to Week 6

Locations

45 sites in 8 countries. Site status is shown where the registry gives one.

  • Alkermes Investigational Site

    Los Angeles, California

  • Alkermes Investigational Site

    Redwood City, California

  • Alkermes Investigator Site

    San Francisco, California

  • Alkermes Investigational Site

    Santa Ana, California

  • Alkermes Investigational Site

    Aurora, Colorado

  • Alkermes Investigational Site

    Colorado Springs, Colorado

  • Alkermes Investigational Site

    Brandon, Florida

  • Alkermes Investigator Site

    Brandon, Florida

  • Alkermes Investigational Site

    Miami, Florida

  • Alkermes Investigator Site

    Winter Park, Florida

  • Alkermes Investigational Site

    Atlanta, Georgia

  • Alkermes Investigational Site

    Macon, Georgia

  • Alkermes Investigational Site

    Stockbridge, Georgia

  • Alkermes Investigator Site

    Peoria, Illinois

  • Alkermes Investigator Site

    Lansing, Michigan

  • Alkermes Investigator Site

    Sterling Heights, Michigan

  • Alkermes Investigator Site

    Lincoln, Nebraska

  • Alkermes Investigational Site

    Middletown, New Jersey

  • Alkermes Investigational Site

    Denver, North Carolina

  • Alkermes Investigational Site

    Huntersville, North Carolina

  • Alkermes Investigator Site

    Canton, Ohio

  • Alkermes Investigational Site

    Cincinnati, Ohio

  • Alkermes Investigational Site

    Cincinnati, Ohio

  • Alkermes Investigational Site

    Dublin, Ohio

  • Alkermes Investigational Site

    Wyomissing, Pennsylvania

  • Alkermes Investigational Site

    Columbia, South Carolina

  • Alkermes Investigational Site

    Austin, Texas

  • Alkermes Investigational Site

    San Antonio, Texas

  • Alkermes Investigational Site

    The Woodlands, Texas

  • Alkermes Investigator Site

    Macquarie Park, New South Wales, Australia

  • Alkermes Investigator Site

    Bedford Park, South Australia, Australia

  • Alkermes Investigational Site

    Alken, Belgium

  • Alkermes Investigational Site

    Bruges, Belgium

  • Alkermes Investigational Site

    Namur, Belgium

  • Alkermes Investigational Site

    Prague, Czechia

  • Alkermes Investigational Site

    Bordeaux, France

  • Alkermes Investigational Site

    Montpellier, France

  • Alkermes Investigational Site

    Bologna, Italy

  • Alkermes Investigational Site

    Milan, Italy

  • Alkermes Investigational Site

    Verona, Italy

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.